When Ghana established the National Vaccine Institute (NVI) after COVID-19, it wasn’t just about health, it was a national security decision.

The pandemic exposed Africa’s dependence on external vaccine supply, making local production not just desirable but essential for sovereignty and resilience.

In our latest Critical Analysis, IMANI examines Ghana’s evolving vaccine ecosystem and Africa’s collective push to produce 60% of its vaccine needs by 2040. The analysis highlights:

Why government’s $50 million seed fund and market assurance policy could make or break the NVI’s sustainability.

The institutional bottlenecks, from regulatory readiness to human capital, threatening Africa’s manufacturing ecosystem.

How achieving the 2040 target will demand coordinated political will, long-term financing, and a strategic move beyond donor dependency.

“Vaccine manufacturing is not a project, it’s a test of Africa’s ability to align health policy with industrial transformation.”

Read the full analysis here:
https://imaniafrica.org/2025/11/ghanas-vaccine-manufacturing-ambition-and-africas-2040-challenge/